Earnings ·
Regeneron Pharmaceuticals reported second quarter 2026 total revenues of $4.3 billion, a 17% increase year-over-year…
REGNRegeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals reported second quarter 2026 total revenues of $4.3 billion, a 17% increase year-over-year, driven by strong commercial performance. Global net sales of Dupixent reached a record $6.0 billion (up 38%), while U.S. EYLEA HD sales rose 52% to $596 million and global Libtayo sales increased 30% to $489 million. GAAP diluted EPS was $12.23, including a $1.02 negative impact from in-process research and development (IPR&D); non-GAAP diluted EPS was $14.29. The company fully repaid the Sanofi Development Balance by the end of the quarter. Regulatory submissions for cemdisiran were accepted for review by the FDA and EMA, with a target FDA action date in November 2026. Additionally, Regeneron declared a quarterly cash dividend of $0.94 per share, payable on August 31, 2026 to shareholders of record as of August 18, 2026. The company operates in the biotechnology industry, inventing and commercializing medicines for serious diseases.